US senators blast Novartis for Zolgensma data falsificationUS politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data Share XUS senators blast Novartis for Zolgensma data falsificationhttps://pharmaphorum.com/news/us-senators-blast-novartis-for-zolgensma-data-falsification/
Trump’s latest drug price reduction scheme? Import from CanadaThe Trump administration has unveiled its latest plan to cut US spending on medicines, and it rests on Share XTrump’s latest drug price reduction scheme? Import from Canadahttps://pharmaphorum.com/news/trumps-latest-drug-price-reduction-scheme-import-from-canada/
Finding the right reimbursement model for gene therapiesWith cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, Share XFinding the right reimbursement model for gene therapieshttps://pharmaphorum.com/views-and-analysis/finding-the-right-reimbursement-model-for-gene-therapies/
Who will pay the price for inaction on superbugs?While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts Share XWho will pay the price for inaction on superbugs?https://pharmaphorum.com/r-d/views-analysis-r-d/who-will-pay-the-price-for-inaction-on-superbugs/
Minister says using generic CF drug is an option in Orkambi rowVertex is coming under increased pressure to sign a deal with the NHS covering its Orkambi cystic fibrosis Share XMinister says using generic CF drug is an option in Orkambi rowhttps://pharmaphorum.com/news/minister-says-using-generic-cf-drug-is-an-option-in-orkambi-row/
Nine for 2019: Challenges impacting pharmaAs we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping Share XNine for 2019: Challenges impacting pharmahttps://pharmaphorum.com/r-d/views-analysis-r-d/nine-for-2019-challenges-impacting-pharma/
On the pulse of ASCO: pricing and clinical trial accessNew survey data from MedPanel, compiled exclusively for pharmaphorum, has revealed US physicians’ thoughts on the topics set Share XOn the pulse of ASCO: pricing and clinical trial accesshttps://pharmaphorum.com/views-analysis-oncology/on-the-pulse-of-asco-pricing-and-clinical-trial-access/
Gilead faces lawsuit over HIV drug pricingGilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving Share XGilead faces lawsuit over HIV drug pricinghttps://pharmaphorum.com/news/gilead-faces-lawsuit-over-hiv-drug-pricing/
VPAS 2024: What should industry consider next time?The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded Share XVPAS 2024: What should industry consider next time?https://pharmaphorum.com/views-analysis-market-access/vpas-2024-what-should-industry-consider-next-time/
